https://bhtherapeutics.com/wp-content/uploads/Jean_Cui.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:33:412024-07-07 21:52:56J. Jean Cui, Ph.D.About
At BlossomHill, we are on a mission to redefine precision medicine and make a leap forward in life expectancy and quality of life for patients.
Our cancer therapies are exquisitely designed to be potent against cancer drivers and aim to address cancer’s resistance to treatment from multiple angles.
Our autoimmune programs seek to tackle difficult challenges to deliver life-changing therapies for patients.
Driven by a desire to transcend incremental improvements to existing drugs, we approach drug design from the ground up. Combining human intelligence, creative thinking, and proven drug design expertise, we are dedicated to developing small-molecule masterpieces that have the potential to set new standards for cancer and autoimmune disease treatment.
Our Story
Mountains and ridges, rivers and streams—it seems like there is no road forward; after a turning point, an enchanting village by a BlossomHill is ahead!
Our name, BlossomHill, was inspired by an ancient Chinese poem that describes a challenging journey overcome through perseverance, eventually leading to hope and opportunity. We believe this symbolizes the patient’s journey through treatment.
SEE MORE
At the heart of BlossomHill is J. Jean Cui, Ph.D., a visionary in drug design, whose desire to improve treatment outcomes for patients led her to found our company and build a world-class pipeline of novel therapeutic candidates.
Inspired to leap beyond the incremental progress in precision medicine, Jean’s deep scientific knowledge and artistic approach breathe life into the concept of creating medical masterpieces to treat disease.
J. Jean Cui, Ph.D., Founder, Inventor, and Drug Designer:
Multiple masterpieces are the mark of a prolific artist.
Dr. J. Jean Cui has a prolific track record as a cancer drug designer and developer. Three molecules designed by Dr. Cui have become market-approved medicines, including repotrectinib (AUGTYRO®), crizotinib (XALKORI®) and lorlatinib (LORBRENA®). Repotrectinib was the lead program in Turning Point Therapeutics’ pipeline, a company founded by Dr. Cui and Peter Li that was eventually acquired by BMS for $4.1 billion in June 2022.
Management
https://bhtherapeutics.com/wp-content/uploads/Jean_Cui.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:33:412024-07-07 21:52:56J. Jean Cui, Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Peter_Li.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:32:282024-07-07 22:13:02Y. Peter Li, Ph.D., MBA
https://bhtherapeutics.com/wp-content/uploads/Vincent_Liptak.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:32:092024-07-07 21:54:54Vincent Liptak, J.D., Ph.D., MBA
https://bhtherapeutics.com/wp-content/uploads/Zachary_Zimmerman.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:31:402024-07-07 22:14:52Zachary F. Zimmerman, M.D., Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Blossomhill-Pingkuan-Headshot.png
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:30:202024-08-12 16:17:23Pingkuan Zhang, M.D.
https://bhtherapeutics.com/wp-content/uploads/Armin_Graber.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:29:442024-07-07 22:15:28Armin Graber, Ph.D., Habil
https://bhtherapeutics.com/wp-content/uploads/Eugene_Rui.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:29:192024-07-07 22:15:59Eugene Y. Rui, Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Jesse_Shao.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:28:352024-07-07 22:17:22Z. Jesse Shao, Ph.D., R.Ph.
https://bhtherapeutics.com/wp-content/uploads/Antonio_Garrido-Montalban.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:28:212024-07-07 22:18:33Antonio Garrido-Montalban, Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Jihao_Zhou.jpg
625
500
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:27:292024-07-07 22:23:23Jihao Zhou, M.D., Ph.D.Board of Directors
https://bhtherapeutics.com/wp-content/uploads/Sundeep_Agrawal.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:25:512024-07-07 22:28:09Sundeep Agrawal, M.D.
https://bhtherapeutics.com/wp-content/uploads/Bihua_Chen.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:25:162024-07-07 22:29:13Bihua Chen
https://bhtherapeutics.com/wp-content/uploads/Jean_Cui-BOD.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:24:582024-07-07 22:30:04J. Jean Cui, Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Carl_Gordon.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:24:442024-07-07 22:31:01Carl L. Gordon, Ph.D., CFA
https://bhtherapeutics.com/wp-content/uploads/George_Lee.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:24:252024-07-07 22:31:34George J. Lee, Ph.D.
https://bhtherapeutics.com/wp-content/uploads/Peter_Li-BOD.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:24:142024-07-07 22:33:18Y. Peter Li, Ph.D., MBA
https://bhtherapeutics.com/wp-content/uploads/Timothy_Stubbs.jpg
400
400
eallison
/wp-content/uploads/BlossomHill-Logo_FullColor.svg
eallison2024-05-28 13:24:012024-07-07 22:37:00Timothy Stubbs, M.D.